Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"The three randomized late-stage clinical trials for MBP8298 (dirucotide) continue to progress very well. We recently announced that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately 510 patients," said Kevin Giese, President and CEO of BioMS Medical. "During the quarter, BioMS was also honored to receive the Gold Leaf Award from BIOTECanada in recognition of our selection as "Company of the Year".

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298 (dirucotide):

(x) MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in Canada and Europe evaluating MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in 10 countries. Patients are administered either MBP8298 (dirucotide) or placebo every six months for a period of two years. To date, there have been eight positive safety reviews from the Data Safety Monitoring Board (DSMB).

(x) MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive MBP8298 (dirucotide) on an un-blinded basis. To date, approximately 95% of patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

(x) MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 (dirucotide) for the treatme
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Rhythm announced today ... of RM-131, the company,s novel ghrelin agonist for the ... The trial demonstrated that RM-131 significantly accelerates early gastric ... 1 diabetic patients with diabetic gastroparesis. The findings were ... Orlando and recently published in ...
(Date:5/20/2013)... On 25-28 July, 2013, UPCP 2013 will convene ... beautiful city of lights. , According to Prof. Eddy ... medical world. Understanding and integrating genetic and molecular information ... transformation. Much of the present medical practice is based ... large cohorts that do not take into account the ...
(Date:5/19/2013)... May 19, 2013 Switzerland’s MS ... announced a new speed record for a transatlantic crossing ... Palmas, Spain, on April 25, 2013, the solar powered ... at the average speed of 5.3 knots before reaching ... May 18, 2013. The first-of-its-kind catamaran completed this year’s ...
(Date:5/17/2013)... 17, 2013 Oven Industries Inc. announces ... 5R6-900 temperature controller has many user-friendly benefits. Contained all ... the wall as a self-contained temperature control ... detail makes the device unique, as well as highly ... also be used universally, which allows the user to ...
Breaking Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6New Temperature Control Products Announced by Oven Industries Inc. 2
... device inventor to drive innovation and product ... development ... Inc.,(OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, ... its Chief,Technical Officer and Vice-President of Research and Development, effective,October ...
... Glycotex, Inc. today announced,enrollment of the first patient ... GLYC-101 on wound closure and cosmetic outcomes in ... on the lower,eyelid area., A previous Phase ... of GLYC-101 at two doses compared to placebo ...
... Emerging Chinese Companies, HAIKOU CITY, Hainan, China, ... Pharma") (OTC Bulletin Board: CPHI),which develops, manufactures, and ... announced the appointment of,The Ruth Group (TRG) as ... President and CEO of China Pharma Holdings, Inc.,commented, ...
Cached Biology Technology:Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 2Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 3China Pharma Holdings, Inc. Appoints The Ruth Group 2China Pharma Holdings, Inc. Appoints The Ruth Group 3
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... to Research Careers) Program has announced the travel ... (SDB) 72nd Annual Meeting in Cancun, Mexico from ... promote the entry of students, postdoctorates and scientists ... basic science community and to encourage the participation ... Meeting. , Awards are given to poster/platform presenters ...
(Date:5/16/2013)... gene involved in neurodegenerative disease also plays a critical ... , In a study of the common fruit ... the clock responsible for sleeping and waking on a ... fruit fly,s sleep-wake cycle is disturbed, making waking up ... , The discovery is particularly interesting because mutations in ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... researching the behavior of field crickets have found for ... based on the latter,s song, and use this information ... crickets compare the information about the attractiveness of available ... attractive males for mating. The finding shows that ...
... the presence of the rare element osmium is on ... consumption of refined platinum, the primary ingredient in catalytic ... smog. A volatile form of osmium is generated during ... cars, and it gets dispersed globally through the atmosphere. ...
... chronic infections in cystic fibrosis patients use one of ... a structure that helps the microbes resist efforts to ... that the bacterial cell-surface sugar, a polysaccharide called Psl, ... a helix, providing a structure that encourages cell-to-cell interaction. ...
Cached Biology News:Remembrance of things past influences how female field crickets select mates 2Remembrance of things past influences how female field crickets select mates 3Increasing levels of rare element found worldwide 2Sugar on bacteria surface serves as base for a web of resistance 2Sugar on bacteria surface serves as base for a web of resistance 3
Human SOST Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: